The delivery of the GDNF family neurotrophic factor neurturin (NRTN) using an AAV2 vector was recently proven to be safe and well tolerated in PD patients, even though the clinical outcome was rather modest (Marks et al. 2008, 2010). This evidence concerns the gene NRTN and Parkinson disease.